Innovative Medicine Backed by the Power of
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, approaches.
Innovative Medicine
Backed by the
Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Innovative Medicine
Backed by the Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Our Approach to Drug Development
- Optimizes R&D Economics
- Shortens Development Timelines
- Increases Probability of Success
AI-based Drug Development
Our neuroscience and immuno-oncology franchises utilize our AI
approach to drug development.
Neuroscience
BXCL501 is an investigational, proprietary, orally dissolving,
thin film formulation of dexmedetomidine designed for the
treatment of agitation and opioid withdrawal symptoms.
Immuno-Oncology
BXCL701 is an investigational, orally-administered, systemic
innate immunity activator in development for the treatment of
aggressive forms of prostate cancer and advanced solid tumors
that are refractory or treatment naïve to
checkpoint inhibitors.
Dec 01, 2021
BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar DisordersVIEW RELEASE
Nov 11, 2021
BioXcel Therapeutics to Present at the 2021 Jefferies London Healthcare ConferenceVIEW RELEASE
Nov 10, 2021
BioXcel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Operational HighlightsVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Dec 06, 2021 10:07 AM
MARKET/SYMBOL
BTAI
PRICE
20.7
CHANGE
-0.76 (-3.54%)
